Accelerate Diagnostics 주식 (NASDAQ: AXDX)

에 대한 최신 뉴스 Accelerate Diagnostics (NASDAQ:AXDX) 주식

Accelerate Diagnostics

Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

Wall Street

Equities

News

Markets

General

$BTC

ACHC

AXDX

COIN

CYBR

KDLY

MVIS

OPRX

SGMO

화요일(13일) 미국 지수 선물은 월요일 증시 급등세를 보인 후 하락했다. 주요 벤치마크 지수의 선물은 개장 전 하락세를 보이고 있다. 



미중 관세 휴전으로 주가가 급등했으며 특히 기술, 임의소비재, 통신 서비스 섹터가 월요일 랠리를 주도했다.

미국 증시, 강력한 상승 이후 하락 개장 예상···전문가 &#34;더 좋은 시기 다가온다&#34;

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

<h3>Gainers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 57.2% to $2.94 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock rose 42.98% to $1.58. The market value of their outstanding shares is at $59.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 40.9% to $1.03. The company's market cap stands at $53.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock increased by 16.2% to $4.41. The company's market cap stands at $255.5 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 15.92% to $64.0. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 15.15% to $1.9. The company's market cap stands at $95.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 95.5% to $0.02 during Tuesday's after-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 44.08% to $0.07. The company's market cap stands at $1.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 36.9% to $296.59. The company's market cap stands at $3.8 billion. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock fell 24.91% to $50.0. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock declined by 23.96% to $10.41. The market value of their outstanding shares is at $62.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) shares decreased by 20.39% to $0.82. The company's market cap stands at $54.6 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APYX

ATPC

HALO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LUCY

OMER

PLRZ

VANI

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 91.4% to $0.03 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELU

CNSP

HCWB

HUMA

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 90.1% to $2.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 25.15% to $0.19. The market value of their outstanding shares is at $4.7 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 23.11% to $0.9. The market value of their outstanding shares is at $46.5 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares moved upwards by 21.22% to $14.05. The company's market cap stands at $381.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) shares moved upwards by 11.22% to $4.26. The market value of their outstanding shares is at $201.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock rose 10.49% to $2.21. The market value of their outstanding shares is at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 91.8% to $0.03 during Tuesday's pre-market session. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock decreased by 36.8% to $0.47. The market value of their outstanding shares is at $106.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 21.63% to $0.11. The company's market cap stands at $2.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares declined by 19.73% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock fell 16.67% to $0.85. The market value of their outstanding shares is at $98.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 16.59% to $0.35. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCT

CHRS

ENTO

GCTK

KLTO

RDHL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in premarket.
Tech, consumer discretionary, and communication services led Monday&#8217;s rally as stocks surged on the<a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling"> tariff truce</a> with China. 
President Donald Trump <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">signed an executive order</a> Monday, seeking to slash U.S. drug prices, fulfilling a social media pledge to achieve cuts of at least 59%. 
Meanwhile, the 10-year Treasury bond yielded 4.45% and the two-year bond was at 3.98%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 91.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.44%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.25%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.42% to $580.57, while the QQQ declined 0.50% to $505.29, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Information technology, consumer discretionary, and communication services sectors saw the biggest gains on Monday. The Dow Jones index soared over 1,100 points as the U.S. and China agreed to a <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">90-day tariff truce</a>, effective May 14. 
This, along with the Trump administration&#8217;s progress to further formal trade talks amid growing economic pressures, fueled the market optimism.
However, this positive Monday followed a down week for major U.S. indices, with the S&amp;P 500, Nasdaq, and Dow all closing lower on Friday.
In stock-specific news, NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported strong first-quarter results, while Kindly MD Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares skyrocketed following a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury strategy merger.
Meanwhile, utility stocks moved against the broader market trend, closing lower.
After Monday, all the indices were out of the correction zone. The S&amp;P 500 index was down 4.93% from its record high of 6,147.43 points, scaled on Feb. 19. Dow Jones was 5.91% lower than its 52-week high of 45,073.63 points, and Nasdaq 100 was 6.09% lower than its previous high of 22,222.61 points.
The Dow Jones index declined 119 points or 0.29% to 41,249.38, whereas the S&amp;P 500 index fell 0.071% to 5,659.91. Nasdaq Composite ended 0.004% higher at 17,928.92, and the small-cap gauge, Russell 2000, dropped 0.16% to 2,023.07.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>4.35%</td>
<td>18,708.34</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>3.26%</td>
<td>5,844.19</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>2.81%</td>
<td>42,410.10</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>3.42%</td>
<td>2,092.20</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick from Carson Research highlighted in an X post that more than 55% of the S&amp;P 500 components made a new 20-day high on Monday.
According to the historical data presented by him, the S&amp;P 500 index ended 16.3% higher on average following days with such fresh 20-day highs. Out of the 30 times this has happened, the index has closed the year on a positive note 29 times.
&#8220;This is yet another clue the lows are likely in and better times are coming,&#8221; Detrick wrote in an X post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&gt;55% of the components in the S&amp;P 500 made a new 20-day high today. This is yet another clue the lows are likely in and better times are coming. Higher a year later 29 out of 30 times and up 16.3% on average. <a href="https://t.co/O0129ED0b9">pic.twitter.com/O0129ED0b9</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922139786845831186?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The S&amp;P 500 index has a year-to-date performance low of 15.3%. Detrick highlighted that &#8220;Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year.&#8221;
Despite having only three such instances historically, he added that 2025 could be the fourth such year.
&#8220;Call me crazy, but this year will be number four,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year. Call me crazy, but this year will be number four. <a href="https://t.co/JnVDNDgUKz">pic.twitter.com/JnVDNDgUKz</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922131292151337121?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
After the 90-day tariff pause between the U.S. and China, John Murillo, chief dealing officer of B2BROKER, a global fintech solutions provider, said that the news triggered an immediate positive market response. 
"Stocks and oil prices have rebounded – apparently, in reaction to the news, which can lead to lower costs for businesses and consumers," Murillo noted.
Despite the initial positive action following the announcement, Murillo emphasized the <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">temporary nature of the agreement</a>. "Now, while the 90-day pause is a big step towards easing tensions, it&#8217;s crucial to remember that it doesn&#8217;t guarantee a complete resolution of the trade war."
Meanwhile, Ed Yardeni, the President of Yardeni Research, has <a href="https://www.benzinga.com/25/05/45367861/ed-yardeni-revises-recession-odds-to-25-after-the-rally-bumps-sp-500-year-end-target-to-6500">lowered his U.S. recession probability</a> to 25% while raising his S&amp;P 500 target to 6,500 points for this year, following the trade deal with China. &#8212;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s NFIB optimism index will be out by 6:00 a.m., whereas headline and core CPI data for April will be released by 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Under Armour Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) rose 1.45% in premarket on Tuesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 8 cents per share on the revenue of $1.16 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Cyberark Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) was up 0.94% as Wall Street expects it to report earnings of 79 cents per share on revenue of $305.23 billion before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) was 1% lower ahead of its earnings. Analysts expect earnings of $1.02 per share on revenue of $37.91 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Acadia Healthcare Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) jumped 4.99% after reporting better-than-expected first-quarter financial results after the closing bell on Monday. The company posted adjusted earnings of 40 cents per share, with revenue of $770.50 million.</li>
</ul>
<ul class="wp-block-list">
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) surged 8.98% after the announcement that the company will join the S&amp;P 500, effective before the opening of trading on Monday, May 19.</li>
</ul>
<ul class="wp-block-list">
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) dropped 31.51% after reporting a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11.</li>
</ul>
<ul class="wp-block-list">
<li>Accelerate Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) slumped 17.97% after it filed for Chapter 11 bankruptcy, leading to a delisting notice from Nasdaq due to non-compliance with listing requirements.</li>
</ul>
<ul class="wp-block-list">
<li>Microvision Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) tumbled 13.22% after reporting a 40% decline in first-quarter revenue, falling to $0.6 million.</li>
</ul>
<ul class="wp-block-list">
<li>OPTIMIZERx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) zoomed 24.89% after it reported strong first-quarter financial results with revenue increasing 11% year-over-year to $21.9 million.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.45% to hover around $62.23 per barrel.
Gold Spot US Dollar rose 0.61% to hover around $3,254.39 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.18% at the 101.6080 level.
Asian markets ended on a mixed note on Tuesday as India's S&amp;P BSE Sensex and Hong Kong's Hang Seng index fell. While South Korea's Kospi, China&#8217;s CSI 300, Japan's Nikkei 225, and Australia's ASX 200 indices advanced. European markets were also mixed in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45368511/china-to-us-goods-shipment-jump-after-90-day-tariff-postponement-a-big-backlog-is-looming">China To US Goods Shipment Jump After 90-Day Tariff Postponement: &#8216;A Big Backlog Is Looming&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

US Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert

Shares of Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose sharply in <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45365186/coinbase-stock-jumps-nearly-11-after-hours-monday-heres-why">today's pre-market trading</a>.
Coinbase is set to join the S&amp;P 500, replacing Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) in the benchmark index, according to a Monday announcement. The inclusion of Coinbase in the S&amp;P 500 will become effective before trading begins on May 19, according to a press release shared by S&amp;P Dow Jones Indices.
Coinbase shares jumped 9.2% to $226.29 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lichen International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) rose 133.6% to $8.13 in pre-market trading after gaining 5% on Monday.</li>
<li>Inno Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) surged 75.8% to $4.15 in pre-market trading. INNO HOLDINGS shares dipped 56% on Monday after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.</li>
<li>Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) gained 58.5% to $11.12 in pre-market trading after New Home Co. agreed to acquire the company for $11.30 per share in an all-cash transaction. Landsea Homes also reported a narrower-than-expected quarterly loss.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) jumped 42.1% to $0.1706 in pre-market trading after gaining 5% on Monday.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 32.8% to $0.9701 in pre-market trading. The company recently posted downbeat quarterly results.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) surged 24.5% to $0.3102 in pre-market trading after gaining more than 43% on Monday.</li>
<li>Profound Medical Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) climbed 23.5% to $5.30 in pre-market trading. The company recently posted downbeat first-quarter results.</li>
<li>GigaCloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) gained 11.6% to $17.74 in pre-market after the company reported better-than-expected first-quarter financial results.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 10% to $15.36 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 92% to $0.0281 in pre-market trading. Polyrizon recently announced its planned reverse split will not be effected.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) fell 48.8% to $0.67 in pre-market trading after jumping 290% on Monday.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell 32.3% to $0.5055 in today's pre-market trading following weaker-than-expected first-quarter results.</li>
<li>Kearny Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) shares dipped 23.5% to $5.00 in pre-market trading after gaining 3% on Monday.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares fell 20.7% to $2.02 in pre-market trading after the company posted weaker-than-expected quarterly results.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) dipped 18.2% to $11.15 in pre-market trading. KindlyMD shares jumped 251% on Monday after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) fell 18% to $0.11 in pre-market trading after dipping 9% on Monday. Accelerate Diagnostics recently announced it filed for Chapter 11 bankruptcy protection.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares tumbled 17% to $0.1448 in pre-market trading after gaining 5% on Monday.</li>
<li>Heritage Commerce Corp (NASDA: HTBK) declined 15.4% to $8.00 in pre-market trading.</li>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 12.1% to $10.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

ARWR

CGBS

DEVS

HTBK

INHD

KRNY

LICN

LSEA

PROF

RGTI

WLGS

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 28.6% to $0.94 during Monday's after-market session. The market value of their outstanding shares is at $48.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares rose 20.01% to $10.99. The market value of their outstanding shares is at $203.2 million. As per the press release, Q1 earnings came out today. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares moved upwards by 13.79% to $3.63. The company's market cap stands at $2.7 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares rose 10.28% to $0.34. The company's market cap stands at $21.1 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares increased by 10.13% to $0.39. The company's market cap stands at $17.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares increased by 9.09% to $0.36. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 88.0% to $0.04 during Monday's after-market session. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 33.28% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 26.13% to $0.31. The company's market cap stands at $1.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock declined by 25.43% to $0.1. The company's market cap stands at $2.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 15.36% to $0.63. The company's market cap stands at $142.0 million. As per the news, the Q1 earnings report came out today. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 10.06% to $0.16. The company's market cap stands at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

HBIO

HEPA

NIVF

PASG

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares increased by 296.0% to $15.45 during Monday's regular session. The company's market cap stands at $92.3 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock rose 93.34% to $1.79. The market value of their outstanding shares is at $143.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares increased by 29.55% to $3.77. The market value of their outstanding shares is at $95.4 million. The company's, Q1 earnings came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 25.98% to $461.12. The market value of their outstanding shares is at $6.0 billion. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) stock increased by 22.76% to $5.5. The market value of their outstanding shares is at $33.6 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 22.75% to $0.79. The market value of their outstanding shares is at $95.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares declined by 28.8% to $4.4 during Monday's regular session. The company's market cap stands at $254.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares declined by 20.0% to $0.12. The company's market cap stands at $2.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 15.02% to $0.52. The company's market cap stands at $1.1 million. </li>
<li>Apimeds Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/APUS#AMEX">APUS</a>) shares fell 13.19% to $1.91. The company's market cap stands at $24.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.18% to $0.14. The company's market cap stands at $4.0 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares declined by 10.69% to $2.92. The market value of their outstanding shares is at $15.6 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGEN

ALGS

APUS

CTMX

IVVD

LPCN

WORX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares rose 39.1% to $35.96 during Thursday's regular session. The company's market cap stands at $2.4 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 38.08% to $6.54. The company's market cap stands at $355.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock increased by 32.83% to $15.6. The company's market cap stands at $276.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) stock increased by 24.11% to $14.41. The market value of their outstanding shares is at $481.3 million. As per the press release, Q1 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock moved upwards by 22.84% to $2.85. The market value of their outstanding shares is at $107.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock increased by 21.64% to $6.88. The company's market cap stands at $343.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 74.5% to $0.12 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 69.32% to $0.16. The company's market cap stands at $20.5 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock decreased by 64.04% to $0.11. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 43.31% to $0.23. The market value of their outstanding shares is at $11.8 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) stock fell 29.1% to $1.17. The market value of their outstanding shares is at $25.3 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares fell 28.83% to $3.44. The market value of their outstanding shares is at $123.9 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVB

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CYRX

DCTH

GNLX

NCNA

QDEL

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Accelerate Diagnostics shares are trading lower after the company announced it filed for Chapter 11 bankruptcy protection

To provide necessary funding during the Chapter 11 proceeding, Accelerate has received a commitment of up to $12.5&nbsp;million in a multi-draw DIP financing facility. Upon approval by the Bankruptcy Court, the DIP financing is expected to provide Accelerate with the necessary liquidity to operate in the normal course and meet obligations to its employees, vendors and customers throughout the Chapter 11 proceeding while executing on the sale process.

Accelerate Diagnostics Files For Chapter 11 Protection; To Sell Substantially All Assets

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 22.9% to $0.44 during Thursday's pre-market session. The market value of their outstanding shares is at $27.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 18.55% to $5.62. The market value of their outstanding shares is at $305.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock rose 16.37% to $1.35. The market value of their outstanding shares is at $22.3 million. </li>
<li>Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) shares moved upwards by 16.18% to $5.6. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock moved upwards by 12.94% to $6.72. The company's market cap stands at $1.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares increased by 12.6% to $2.77. The company's market cap stands at $723.6 million. As per the press release, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 63.4% to $0.11 during Thursday's pre-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 29.2% to $0.33. The company's market cap stands at $8.2 million. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) shares fell 14.69% to $5.81. The market value of their outstanding shares is at $41.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares decreased by 13.47% to $5.91. The market value of their outstanding shares is at $106.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 13.32% to $0.59. The market value of their outstanding shares is at $2.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 12.5% to $0.01. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

AVAH

CGTX

ECOR

LGMK

MIRA

NVAX

ZVSA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE&#x2122; system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.
The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.5 hours, enabling same shift targeted antimicrobial therapy for patients with serious infections.
With a user-friendly workflow, high throughput capacity, and scalable design, once approved by the FDA, the WAVE system will offer microbiology laboratories a comprehensive AST solution to meet a wide range of testing demands and hospital formulary needs.
According to the World Health Organization, sepsis affects an estimated 49 million people globally each year, resulting in approximately 11 million deaths.1&nbsp; Of those, around 1.32 million deaths2 are attributed to bacterial antimicrobial resistance. Sepsis also represents the most significant cost burden to the U.S. healthcare system, with an estimated annual expense of $62 billion.3
By delivering rapid AST results, the WAVE system is designed to support earlier, targeted antimicrobial therapy—improving patient outcomes, reducing hospital costs, and helping combat antimicrobial resistance.

Biotech

Accelerate Diagnostics Submits Its Accelerate WAVE System And Positive Blood Culture Gram-Negative Test Kit To The U.S. FDA For 510(k) Clearance

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly sales of $2.800 million which missed the analyst consensus estimate of $3.020 million by 7.28 percent. This is a 7.50 percent decrease over sales of $3.027 million the same period last year.

Earnings

Earnings Misses

Accelerate Diagnostics Q4 Sales $2.800M Miss $3.020M Estimate

2024 Fourth Quarter and Full-Year Financial Results
<ul>
<li>Preliminary revenue was approximately $11.7 million for the year, compared to $12.1 million in the prior year. While year-over-year revenues for consumable products increased by approximately 3%, overall revenue was down year-over-year due to lower revenues from capital sales of Pheno instruments compared to the prior year. &nbsp;</li>
<li>Ended the year with approximately $16.3 million in cash and cash equivalents, compared to $20.9&nbsp;million at the start of the fourth quarter, a reduction in cash and cash equivalents for the fourth quarter of 2024 of $4.5 million. This reflects our continued reduction in operating cash use over the prior quarters of 2024.</li>
</ul>

Guidance

Accelerate Q4 Revenue Of $11.7 Vs $12.1M YoY, $16.3M Cash Ending 2024; 3% Rise In Consumable Revenue Amid Pheno Capital Sales Decline

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent. This is a 9.82 percent decrease over sales of $3.299 million the same period last year.

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR)
Enables rapid, automated microbial identification on the Bruker MALDI Biotyper&#xAE; CA System directly from positive blood culture samples
TUCSON, Ariz., Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper&#xAE; CA &nbsp;System (MBT-CA System) and MBT-CA Sepsityper&#xAE; software extension.
Designed for clinical laboratories, the Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification (ID) using Bruker's MBT-CA system. This eliminates the need for overnight culture methods, reducing the wait time for microbial ID results, which is critical in the fight against sepsis.
The Accelerate Arc system is designed to leverage the breadth of the Bruker MBT-CA reference library to provide rapid ID. This, in conjunction with our future rapid phenotypic antibiotic susceptibility testing (AST) innovation, the Accelerate WAVE&#x2122; system1, can enable same shift reporting to Antimicrobial Stewardship teams and clinicians alike. By providing clinicians with rapid ID and AST results, clinicians can get the patient on the optimal antibiotic therapy many hours sooner, which has been shown to improve patient outcomes with Sepsis, reduce antimicrobial resistance rates and hospital costs.

Accelerate Diagnostics Announces FDA Clearance Of Its Accelerate Arc System, An Automated Platform Designed To Fight Against Sepsis And Antimicrobial Resistance

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.55) by 9.09 percent. This is a 83.16 percent increase over losses of $(2.97) per share from the same period last year. The company reported quarterly sales of $2.99 million which missed the analyst consensus estimate of $3.01 million by 0.80 percent. This is a 2.23 percent increase over sales of $2.92 million the same period last year.

Earnings Beats

Accelerate Diagnostics Q2 EPS $(0.50) Beats $(0.55) Estimate, Sales $2.99M Miss $3.01M Estimate

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average.
It is estimated by the World Health Organization, Sepsis affects an estimated 49 million1 people globally each year, causing an estimated 11 million1 deaths of which an estimated 1.32 million are attributed to bacterial antimicrobial resistance. Additionally, Sepsis is the number one cost to the US healthcare system with an annual estimated expense of $62 billion3.&nbsp;By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance.

Accelerate Diagnostics Announces Completion Of Its WAVE Pre-Clinical Trial Designed To Deliver Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Culture Bottles And Bacterial Isolated Colonies To Report Accurate Results Within 4.5 Hours, On Average

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares increased by 9.01% to $1.39. The market value of their outstanding shares is at $30.6 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock increased by 8.28% to $1.83. The company's market cap stands at $4.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) shares fell 26.5% to $3.38 during Thursday's after-market session. The market value of their outstanding shares is at $91.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock decreased by 10.64% to $0.42. The company's market cap stands at $3.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 5.0% to $0.61. The market value of their outstanding shares is at $10.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 4.93% to $1.93. The market value of their outstanding shares is at $1.9 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 4.89% to $0.76. The company's market cap stands at $19.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 4.88% to $0.39. The company's market cap stands at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BIOR

BMRA

EVOK

GOVX

HLTH

ONMD

PPBT

TIVC

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) shares increased by 28.6% to $5.53. The company's market cap stands at $149.2 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares moved upwards by 24.55% to $0.54. The market value of their outstanding shares is at $10.3 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares rose 23.93% to $1.14. The company's market cap stands at $12.1 million. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) shares rose 21.98% to $2.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares increased by 16.25% to $1.02. The market value of their outstanding shares is at $22.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) stock fell 32.8% to $0.41 during Tuesday's regular session. The company's market cap stands at $41.4 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares declined by 27.76% to $1.9. The company's market cap stands at $19.3 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares fell 25.44% to $0.1. The market value of their outstanding shares is at $3.4 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock fell 25.13% to $0.12. The market value of their outstanding shares is at $7.8 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares decreased by 20.67% to $0.18. The company's market cap stands at $2.8 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares fell 20.4% to $6.21. The company's market cap stands at $8.5 million. As per the news, the Q1 earnings report came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AONC

BDRX

BNOX

DARE

GTBP

NVOS

SCPX

SNOA

XYLO

Small Cap

Press Releases

Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results

Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial

Accelerate Diagnostics Reports Second Quarter 2024 Financial Results

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

Aethlon Medical

Autonomix Medical

Bluejay Diagnostics

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Know Labs

LogicMark

NanoVibronix

ENDRA Life Sciences

Nuwellis

Predictive Oncology

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Technologies

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Tenon Medical

Venus Concept

Catheter Precision

Craig-Hallum

화요일(13일) 미국 지수 선물은 월요일 증시 급등세를 보인 후 하락했다. 주요 벤치마크 지수의 선물은 개장 전 하락세를 보이고 있다.&nbsp;



미중 <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">관세 휴전</a>으로 주가가 급등했으며 특히 기술, 임의소비재, 통신 서비스 섹터가 월요일 랠리를 주도했다.



도널드 트럼프 대통령은 월요일 미국 약값을 최소 59% 인하하겠다는 소셜 미디어 공약을 이행하기 위해 미국 약가 인하를 담은 <a href="http://"https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80"" target="_blank" rel="noreferrer noopener">행정명령에 서명했다.</a>



한편 10년 만기 국채 수익률은 4.45%, 2년 만기 국채는 3.98%를 기록했다. CME 그룹의 <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html" target="_blank" rel="noreferrer noopener">FedWatch </a><a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">도구</a> 예측에 따르면 시장은 6월 FOMC 회의에서 연준이 현재 금리를 동결할 확률은 91.8%이다.



<figure class="wp-block-table is-style-stripes">
<table class="has-fixed-layout">
<tbody>
<tr>
<td>지수 선물</td>
<td>변동 (+/-)</td>
</tr>
<tr>
<td>다우존스</td>
<td>-0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.44%</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>-0.25%</td>
</tr>
</tbody>
</table>
</figure>



각각 S&amp;P 500 지수와 나스닥 100 지수를 추종하는&nbsp;SPDR S&amp;P 500 ETF 신탁(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) 및&nbsp;인베스코 QQQ 신탁 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 화요일 프리마켓에서 하락했다. SPY는 580.57달러로 0.42% 하락했으며, QQQ는 505.29달러 0.50% 하락했다.



<h3 class="wp-block-heading">지난 세션에서의 힌트</h3>



월요일에는 정보 기술, 임의소비재, 통신 서비스 섹터가 가장 큰 상승세를 보였다. 미국과 중국이 5월 14일부터 <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling" target="_blank" rel="noreferrer noopener">90일간 관세 휴전</a>에 합의하면서 다우존스 지수는 1,100포인트 이상 급등했다. 



이는 경제 압박이 커지는 가운데 트럼프 행정부가 공식적인 무역 협상을 진전시킨 것과 함께 시장 낙관론에 불을 지폈다.



개별 주식 뉴스 중에서는&nbsp;NRG 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)가 1분기 강력한 실적을 보고했으며, 킨들리 MD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) 주가는&nbsp;비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)의 재무 전략 합병 소식에 급등했다.



반면 유틸리티 섹터는 전반적인 시장 추세와 반대로 움직이며 하락 마감했다.



월요일 이후 모든 지수는 조정 구간에서 벗어났다. S&amp;P 500 지수는 2월 19일 기록한 사상 최고치인 6,147.43포인트에서 4.93% 낮은 수준이다. 다우존스 지수는 52주 최고치인 45,073.63포인트보다 5.91% 낮고, 나스닥 100 지수는 전고점인 22,222.61포인트보다 6.09% 낮다.



<figure class="wp-block-table is-style-stripes">
<table class="has-fixed-layout">
<tbody>
<tr>
<td>지수</td>
<td>변동 (+/-)</td>
<td>값 (포인트)</td>
</tr>
<tr>
<td>나스닥 종합</td>
<td>4.35%</td>
<td>18,708.34</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>3.26%</td>
<td>5,844.19</td>
</tr>
<tr>
<td>다우존스</td>
<td>2.81%</td>
<td>42,410.10</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>3.42%</td>
<td>2,092.20</td>
</tr>
</tbody>
</table>
</figure>



<h3 class="wp-block-heading">애널리스트의 통찰:</h3>



카슨 리서치의 라이언 디트릭은 소셜미디어 엑스(X) 포스팅에서 S&amp;P 500 구성종목의 55% 이상이 월요일에 20일래 최고치를 경신했다고 강조했다.



그가 제시한 과거 데이터에 따르면, S&amp;P 500 지수는 20일 최고치를 기록한 다음 날 평균 16.3% 상승 마감했다. 이런 일이 발생한 30차례 중 지수는 29차례 해당 연도를 상승 마감했다.



"이것은 저점을 찍고 더 좋은 시기가 다가오고 있다는 또 다른 단서다.&#8221;



<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&gt;55% of the components in the S&amp;P 500 made a new 20-day high today. This is yet another clue the lows are likely in and better times are coming. Higher a year later 29 out of 30 times and up 16.3% on average. <a href="https://t.co/O0129ED0b9">pic.twitter.com/O0129ED0b9</a>&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922139786845831186?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
</div></figure>



S&amp;P 500 지수의 연초 대비 수익률은 15.3%로 최저치를 기록했다. 디트릭은 "역사상 S&amp;P 500 지수가 연초 대비 15% 이상 하락했다가 연말에 다시 플러스로 돌아선 경우는 단 세 번뿐"이라고 강조했다.



역사적으로 그런 경우는 단 세 번뿐이지만 2025년이 네 번째가 될 수 있다고 덧붙였다.



"내가 미쳤다고 하겠지만 올해는 네 번째가 될 것이다.&#8221;



<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year. Call me crazy, but this year will be number four. <a href="https://t.co/JnVDNDgUKz">pic.twitter.com/JnVDNDgUKz</a>&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922131292151337121?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
</div></figure>



미국과 중국 간의 90일 관세 유예가 발표된 후, 글로벌 핀테크 솔루션 제공업체인 B2BROKER의 최고 거래 책임자인 존 무릴로(John Murillo)는 이 소식이 즉각적으로 긍정적인 시장 반응을 불러일으켰다고 말했다.



그는 "관세 유예 소식에 대한 반응으로 주식과 유가가 반등했으며, 이는 기업과 소비자의 비용 절감으로 이어질 수 있다&#8221;고 했다.



발표 후 초기 긍정적인 반응에도 불구하고 무릴로는 <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war" target="_blank" rel="noreferrer noopener">이번 합의의 일시적인 성격</a>을 강조했다. "90일간의 일시 중단은 긴장 완화를 위한 큰 진전이지만, 무역전쟁의 완전한 해결을 보장하지는 않는다는 점을 기억하는 것이 중요하다."



한편, 야데니 리서치의 대표인 에드 야데니는 중국과의 무역 합의 이후 <a href="https://www.benzinga.com/25/05/45367861/ed-yardeni-revises-recession-odds-to-25-after-the-rally-bumps-sp-500-year-end-target-to-6500" target="_blank" rel="noreferrer noopener">미국 경기 침체 가능성</a>을 25%로 낮추고 올해 S&amp;P 500 목표치를 6,500포인트로 상향 조정했다. 



투자자들이 화요일에 주목할 사항은 다음과 같다:



곧 발표되는 경제지표



<ul class="wp-block-list">
<li>4월의 NFIB 낙관 지수는 화요일(13일) 오전 6시까지 발표될 예정이며, 4월의 주요 및 핵심 CPI 데이터는 오전 8시 30분(ET)에 발표된다.</li>
</ul>



주목할 주식:



<ul class="wp-block-list">
<li>언더 아머(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>): 화요일 프리마켓에서 2.74% 상승 중이며 개장 전 실적 발표가 예상된다. 애널리스트들은 주당 8센트의 분기 수익과 11억 6천만 달러 매출을 예상하고 있다.</li>



<li>사이버아크 소프트웨어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>)는 개장 전 실적 발표 예정이며 주당순이익 79센트, 매출 3,052억 3천만 달러가 예상된다. 화요일 프리마켓에서 0.94% 상승 중이다.</li>



<li>JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>): 실적 발표를 앞두고 1% 하락했다. 애널리스트들은 주당 1.02달러의 실적과 379억 1천만 달러 매출을 예상한다. </li>



<li>아카디아 헬스케어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>): 월요일 장 마감 후 기대 이상의 1분기 재무 결과를 보고한 후 4.99% 급등했다. 회사는 주당 40센트의 조정된 실적과 7억 7,050만 달러의 매출을 보고했다.</li>



<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 월요일 5월 19일 S&amp;P 500 지수에 편입된다는 발표 후 애프터마켓에서 8.98% 급등했다.</li>



<li>상가모 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>): 분기 주당 0.14달러의 손실을 보고한 후 31.51% 하락했는데, 이는 잭스 컨센서스 추정치인 0.11달러의 손실과 대비되는 수치였다.</li>



<li>엑셀러레이트 다이아그노스틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>): 챕터 11 파산을 신청한 후 17.97% 하락했으며, 나스닥의 상장 요건 불이행으로 인한 상장 폐지 통지를 받았다.</li>



<li>마이크로비전(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>): 1분기 매출이 40% 감소하여 60만 달러로 떨어진 후 13.22% 하락했다.</li>



<li>옵티마이즈알엑스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>): 1분기 재무 실적이 강력하게 보고되었다. 매출이 전년 대비 11% 증가하여 2,190만 달러에 이르렀고 주가는 24.89% 급등했다.</li>
</ul>



원자재, 금, 및 글로벌 주식 시장



원유 선물은 뉴욕 초기 세션에서 0.45% 상승하여 배럴당 62.23달러에 거래되고 있다.



금 현물은 0.61% 상승하여 온스당 3,254.39달러에 거래되고 있다. 마지막 기록 최고가는 온스당 3,500.33달러였다. 미국 달러 지수는 0.18% 하락하여 101.6080 수준이다.



아시아 시장은 화요일에 혼조세로 마감했다. 인도의 S&amp;P BSE 센섹스와 홍콩의 항셍지수는 하락했다. 반면에 한국의 코스피, 중국의 CSI 300, 일본의 닛케이 225, 호주의 ASX 200 지수는 상승했으며, 유럽 시장은 초기 거래에서 혼조세를 보이고 있다.



다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.



Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

미국 증시, 강력한 상승 이후 하락 개장 예상···전문가 "더 좋은 시기 다가온다"

Comments

Accelerate Diagnostics

뉴스

에 대한 최신 뉴스 Accelerate Diagnostics (NASDAQ:AXDX) 주식

화요일, 5월 13, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌